Blood test that predicts Alzheimer's disease
The test can detect the disease up to three years before the onset of symptoms, however it is only 90 per cent accurate
Steve Connor is the Science Editor of The Independent and i. He has won many awards for his journalism, including five-times winner of the prestigious British science writers’ award; the David Perlman Award of the American Geophysical Union; four times highly commended as specialist journalist of the year in the UK Press Awards; UK health journalist of the year and a special merit award of the European School of Oncology for his investigations into the tobacco industry. He has a degree in zoology from the University of Oxford and has a special interest in genetics and medical science, human evolution and origins, climate change and the environment.
Sunday 09 March 2014
A blood test that can detect Alzheimer’s disease up to three years before the onset of symptoms has been developed by scientists who believe that it could lead to the early diagnosis of progressive dementia in elderly people.
The test raises ethical concerns, however, as it is only 90 per cent accurate in its current form – meaning that up to one in ten people could be wrongly diagnosed with a disease for which there is no effective treatment.
Researchers nevertheless believe that a blood test for Alzheimer’s could help in the search for a therapy or cure by identifying those people in the population at highest risk and who could therefore benefit most from experimental treatments.
The blood test is based on analysing the fatty chemicals – known as lipids – circulating in the bloodstream, which begin to change as a result of a breakdown in the membranes of the brain cells associated with Alzheimer’s.
Scientists have known that Alzheimer’s disease begins long before the onset of the diagnostic symptoms, such as memory loss or confusion, and have tried for many years to find ways of detecting these changes with simple tests that could be used in the clinic.
A team of researchers led by Howard Federoff of Georgetown University Medical Centre in Washington identified 10 lipids in the blood that can be used to detect the early signs of Alzheimer’s or other forms of dementia, which affects one in three people over the age of 65.
“Our novel blood test offers the potential to identify people at risk for progressive cognitive decline and can change how patients, their families and treating physicians plan for and manage the disorder,” Dr Federoff said.
“If there were to be a test that could be ordered by a clinician to determine Alzheimer’s risk, the patient, along with their family and clinician, would have to determine what’s right for them: test or not test. If so, the testing process would need to be managed and could involve counselling akin to [gene tests] for cancer risk,” he told The Independent.
Doug Brown, director of research and development at the Alzheimer’s Society, said it is the first time that a blood test has been developed for the disorder, but there are problems in working out how it can be used in practice.
“Having such a test would be an interesting development, but it also throws up ethical considerations. If this does develop in the future, people must be given a choice about whether they would want to know, and fully understand the implications,” Dr Brown said.
The study, published in the journal Nature Medicine, involved taking blood samples from 525 healthy volunteers over the age of 70 who were monitored over five years to see whether they went on to develop mild dementia or Alzheimer’s.
The researchers identified the 10 lipids after some of the volunteers were showing the first signs of dementia, and then used the same panel of “biomarkers” to predict whether the other volunteers will go on to develop the disorder.
“The lipid panel was able to distinguish with 90 per cent accuracy these two distinct groups – cognitively normal participants who would progress to mild cognitive impairment or Alzheimer’s disease within two to three years, and those who would remain normal in the near future,” Dr Federoff said.
Although further research is needed to validate the results and improve the accuracy, a test could be used commercially within a few years, especially to identify people at risk who could take part in clinical trials of prototype treatments, he said.
“Such a test would identify high-risk individuals who might then be eligible to participate in clinical trials, testing therapies that might halt or prevent disease progression,” Dr Ferderoff said.
“The pre-clinical state of the disease offers a window of opportunity for timely disease-modifying intervention. Biomarkers such as ours that define this asymptomatic period are critical for successful,” he said.
“We consider our results a major step toward the commercialisation of a pre-clinical disease biomarker test that could be useful for large-scale screening to identify at-risk individuals.
“We’re designing a clinical trial where we’ll use this panel to identify people at high risk for Alzheimer’s to test a therapeutic agent that might delay or prevent the emergence of the disease,” he added.
Life & Style blogs
Video shows how to turn your phone into a 3D hologram
Gill Pharaoh: Healthy former nurse, 75, passes away at assisted dying clinic after deciding old age is 'awful'
Free porn websites could be shut down within months, says David Cameron
The difference between a psychopath and a sociopath
National Orgasm Day: Six reasons (plus one bogus one) why they're good for us
- 1 Video shows how to turn your phone into a 3D hologram
- 2 Artist Jamie McCartney: How The Great Wall of Vagina is a stand against 'body fascism'
- 3 Katie Hopkins reveals fear she will die during brain surgery to cure epilepsy
- 4 'Gene drive': Scientists sound alarm over supercharged GM organisms which could spread in the wild and cause environmental disasters
- 5 Dutch King Willem-Alexander declares the end of the welfare state
Up to 70k DOE: Guru Careers: We are seeking an experienced Financial Director ...
£30000 - £40000 per annum: Recruitment Genius: This is a fantastic and interes...
£16224 - £20280 per annum: Recruitment Genius: A Warehouse & Stores Supervisor...
£35000 - £39000 per annum: Recruitment Genius: This is an exciting opportunity...